Patient characteristics by type of IDH mutation and MRD status
| Patient characteristic . | Mutant IDH1 MRD absent (N = 44) . | Mutant IDH1 MRD present (N = 29) . | P value IDH1 . | Mutant IDH2 MRD absent (N = 49) . | Mutant IDH2 MRD present (N = 43) . | P value IDH2 . |
|---|---|---|---|---|---|---|
| HOVON trial, n (%) | .548 | .231 | ||||
| HO42A | 4 (9.1) | 5 (17.2) | 12 (24.5) | 4 (9.3) | ||
| HO92 | 4 (9.1) | 1 (3.4) | 3 (6.1) | 2 (4.7) | ||
| HO102 | 11 (25.0) | 5 (17.2) | 11 (22.4) | 10 (23.3) | ||
| HO132 | 25 (56.8) | 18 (62.1) | 23 (46.9) | 27 (62.8) | ||
| Age, median (range), y | 50 (27-65) | 57 (20-65) | .122 | 51 (19-64) | 58 (26-65) | .003 |
| Sex, n (%) | .340 | .528 | ||||
| Male | 28 (63.6) | 15 (51.7) | 30 (61.2) | 23 (53.5) | ||
| Female | 16 (36.4) | 14 (48.3) | 19 (38.8) | 20 (46.5) | ||
| White blood cell count at entry, n (%) | .392 | .336 | ||||
| ≤100 × 109/L | 39 (88.6) | 28 (96.6) | 48 (98.0) | 40 (93.0) | ||
| >100 × 109/L | 5 (11.4) | 1 (3.4) | 1 (2.0) | 3 (7.0) | ||
| Last treatment before CR, n (%) | .181 | .311 | ||||
| Cycle 1 | 40 (90.9) | 23 (79.3) | 41 (83.7) | 32 (74.4) | ||
| Cycle 2 | 4 (9.1) | 6 (20.7) | 8 (16.3) | 11 (25.6) | ||
| Consolidation therapy, n (%) | .014 | .041 | ||||
| No consolidation | 1 (2.3) | 5 (17.2) | 1 (2.0) | 8 (18.6) | ||
| Third cycle chemotherapy | 6 (13.6) | 4 (13.8) | 12 (24.5) | 6 (14.0) | ||
| Autologous HSCT | 23 (52.3) | 6 (20.7) | 15 (30.6) | 14 (32.6) | ||
| Allogeneic HSCT | 14 (31.8) | 14 (48.3) | 21 (42.9) | 15 (34.9) | ||
| ELN risk classification 2022, n (%) | .274 | .043 | ||||
| Favorable | 22 (50.0) | 9 (31.0) | 21 (42.9) | 10 (23.3) | ||
| Intermediate | 11 (25.0) | 10 (34.5) | 19 (38.8) | 16 (37.2) | ||
| Adverse | 11 (25.0) | 10 (34.5) | 9 (18.4) | 17 (39.5) | ||
| Mutations, n (%) | ||||||
| Mutant NPM1 | 28 (63.6) | 13 (44.8) | .150 | 27 (55.1) | 22 (51.2) | .834 |
| Mutant FLT3-ITD | 9 (20.5) | 5 (17.2) | 1.000 | 10 (20.4) | 17 (39.5) | .066 |
| Mutant TP53 | 1 (2.3) | 2 (6.9) | .559 | 1 (2.0) | 0 (0) | 1.000 |
| Myelodysplasia-related gene mutations | 14 (31.8) | 10 (34.5) | 1.000 | 11 (22.4) | 20 (46.5) | .017 |
| Cytogenetics, n (%)∗ | ||||||
| Normal karyotype | 33 (75.0) | 22 (75.9) | .782 | 37 (75.5) | 34 (79.1) | 1.000 |
| Complex karyotype ELN2022 | 1 (2.3) | 2 (6.9) | .563 | 1 (2.0) | 1 (2.3) | 1.000 |
| Patient characteristic . | Mutant IDH1 MRD absent (N = 44) . | Mutant IDH1 MRD present (N = 29) . | P value IDH1 . | Mutant IDH2 MRD absent (N = 49) . | Mutant IDH2 MRD present (N = 43) . | P value IDH2 . |
|---|---|---|---|---|---|---|
| HOVON trial, n (%) | .548 | .231 | ||||
| HO42A | 4 (9.1) | 5 (17.2) | 12 (24.5) | 4 (9.3) | ||
| HO92 | 4 (9.1) | 1 (3.4) | 3 (6.1) | 2 (4.7) | ||
| HO102 | 11 (25.0) | 5 (17.2) | 11 (22.4) | 10 (23.3) | ||
| HO132 | 25 (56.8) | 18 (62.1) | 23 (46.9) | 27 (62.8) | ||
| Age, median (range), y | 50 (27-65) | 57 (20-65) | .122 | 51 (19-64) | 58 (26-65) | .003 |
| Sex, n (%) | .340 | .528 | ||||
| Male | 28 (63.6) | 15 (51.7) | 30 (61.2) | 23 (53.5) | ||
| Female | 16 (36.4) | 14 (48.3) | 19 (38.8) | 20 (46.5) | ||
| White blood cell count at entry, n (%) | .392 | .336 | ||||
| ≤100 × 109/L | 39 (88.6) | 28 (96.6) | 48 (98.0) | 40 (93.0) | ||
| >100 × 109/L | 5 (11.4) | 1 (3.4) | 1 (2.0) | 3 (7.0) | ||
| Last treatment before CR, n (%) | .181 | .311 | ||||
| Cycle 1 | 40 (90.9) | 23 (79.3) | 41 (83.7) | 32 (74.4) | ||
| Cycle 2 | 4 (9.1) | 6 (20.7) | 8 (16.3) | 11 (25.6) | ||
| Consolidation therapy, n (%) | .014 | .041 | ||||
| No consolidation | 1 (2.3) | 5 (17.2) | 1 (2.0) | 8 (18.6) | ||
| Third cycle chemotherapy | 6 (13.6) | 4 (13.8) | 12 (24.5) | 6 (14.0) | ||
| Autologous HSCT | 23 (52.3) | 6 (20.7) | 15 (30.6) | 14 (32.6) | ||
| Allogeneic HSCT | 14 (31.8) | 14 (48.3) | 21 (42.9) | 15 (34.9) | ||
| ELN risk classification 2022, n (%) | .274 | .043 | ||||
| Favorable | 22 (50.0) | 9 (31.0) | 21 (42.9) | 10 (23.3) | ||
| Intermediate | 11 (25.0) | 10 (34.5) | 19 (38.8) | 16 (37.2) | ||
| Adverse | 11 (25.0) | 10 (34.5) | 9 (18.4) | 17 (39.5) | ||
| Mutations, n (%) | ||||||
| Mutant NPM1 | 28 (63.6) | 13 (44.8) | .150 | 27 (55.1) | 22 (51.2) | .834 |
| Mutant FLT3-ITD | 9 (20.5) | 5 (17.2) | 1.000 | 10 (20.4) | 17 (39.5) | .066 |
| Mutant TP53 | 1 (2.3) | 2 (6.9) | .559 | 1 (2.0) | 0 (0) | 1.000 |
| Myelodysplasia-related gene mutations | 14 (31.8) | 10 (34.5) | 1.000 | 11 (22.4) | 20 (46.5) | .017 |
| Cytogenetics, n (%)∗ | ||||||
| Normal karyotype | 33 (75.0) | 22 (75.9) | .782 | 37 (75.5) | 34 (79.1) | 1.000 |
| Complex karyotype ELN2022 | 1 (2.3) | 2 (6.9) | .563 | 1 (2.0) | 1 (2.3) | 1.000 |
HSCT, hematopoietic stem cell transplantation.
Missing data for 3 patients.